Update on the acute treatment of hereditary angioedema

Allergy and Asthma Proceedings

Volumn 32, Issue 1, 2011, Pages 11-16

  Riedl, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; ECALLANTIDE; ICATIBANT; INFUSION FLUID; KALBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANGIONEUROTIC EDEMA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INJECTION SITE REACTION; NONHUMAN; ORGANIZATION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; PEPTIDES; TREATMENT OUTCOME;

EID: 79251616362     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3406     Document Type: Review

References (41)

1. Frank MM. Hereditary angioedema: The clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 26:653-668, 2006.
2. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
3. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 98:383-388, 2007. (Pubitemid 46582131)
4. Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: What is the evidence? Int J Clin Pract 59:594-599, 2005.
5. Zuraw BL. Hereditary angiodema: A current state-of-the-art review, IV: Short-and long-term treatment of hereditary angioedema: Out with the old and in with the new? Ann Allergy Asthma Immunol 100:S13-S18, 2008.
6. Zuraw BL, and Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc 30: 487-492, 2009.
7. Davis AE III. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy 6:2, 2008.
8. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med 15:69-78, 2009.
9. Gadek JE, Hosea SW, Gelfand JA, at al. Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 302:542-546, 1980.
10. Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 44:299-301, 1980. (Pubitemid 10110161)
11. Kaplan AP, and Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 104:193-204, 2010.
12. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 8:3173-3181, 2007.
13. Bork K, and Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161:714-718, 2001.
14. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774-1784, 2005.
15. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522, 2010.
16. U.S. Food and Drug Administration. Cinryze (C1INH) for routine prophylaxis against HAE attacks: Final Clinical Review. Available online at www.fda.gov/downloads/BiologicsBlood Vaccines/BloodBloodProducts/ ApprovedProducts/Licensed ProductsBLAs/FractionatedPlasmaProducts/ucm094092.pdf; last accessed June 20, 2010.
17. De Serres J, Gröner A, and Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apher Sci 29:247-254, 2003. (Pubitemid 37321355)
18. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801-808, 2009.
19. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:S51-S131, 2004.
20. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 116:876-883, 2005.
21. Zuraw B, Cicardi M, Levy R, et al. Recombinent human C1- inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821-827, 2010.
22. Hack CE, Relan A, Haase G, et al. IgE against rabbit allergens and therapeutic use of recombinant human C1 inhibitor in hereditary angioedema. Presented at the 2010 annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI), London, June 6, 2010. Allergy 65(suppl 92): 445.
23. Baboeram A. Relan A, Hace CE, et al. Immunogenicity assessment of recombinant human C1 inhibitor. Presented at the 2010 annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI), London, June 6, 2010.
24. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109:1057-1063, 2002.
25. Nussberger J, Cugno M, Cicardi M, et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104:1321-1322, 1999.
26. Bernstein JA, and Qazi M. Ecallantide: Its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 6:29-39, 2010.
27. Vernon MK, Rentz AM, Wyrwich KW, et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18:929-939, 2009.
28. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks of hereditary angioedema. N Engl J Med 363:523-531, 2010.
29. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529, 2010.
30. Horn PT, Li HH, and Pullman WE. Hypersensitivity reactions following ecallantide treatment for acute attacks of HAE. Presented at the meeting of the American Academy of Allergy, Asthma, and Immunology, New Orleans, LA, February 27, 2010. J Allergy Clin Immun 125(suppl 1): AB163.
31. Dyax Corp. Kalbitor package insert. Cambridge, MA; Revised, December, 2009.
32. Deeks ED. Icatibant. Drugs 70:73-81, 2010.
33. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin- receptor antagonist, in hereditary angioedema. N Eng J Med 363:532-541, 2010.
34. European Medicines Agency. CHMP assessment report for Firazyr. Available online at www.ema.europa.eu/humandocs/ PDFs/EPAR/firazyr/H-899-en6.pdf; last accessed June 20, 2010.
35. Zuraw B, Yasothan U, and Kirkpatrick P. Ecallantide. Nat Rev Drug Discov 9:189-190, 2010.
36. Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 102:366-372, 2009.
37. Bork K, Bygum A, and Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153-161, 2008.
38. Széplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 115:864-869, 2005.
39. Bygum A, Andersen KE, and Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19:147-151, 2009.
40. Levi M, Choi G, Picavet C, et al. Self-administration of C1- inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 117:904-908, 2006.
41. Longhurst HJ, Carr S, and Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: A viable, effective treatment option. Clin Exp Immunol 147:11-17, 2007.